Sandoz resubmits biosimilar pegfilgrastim application to US FDA

NEXT STORY
Oncology Venture har bekräftat registreringsstrategin för dovitinib och utvecklat ny DRP-kombinationsbiomarkör för PD1 / PD-L1 + dovitinib – inleder utlicensieringsaktiviteter med Destum Partners
PREV STORY
Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Experts from the American Institutes for Research and IMPAQ to Present at the 2021 AcademyHealth Virtual Annual Research Meeting

author_avatar
NASDAQ Market News

Provation Announces Addition of New Pulmonology Module to Cloud-Based Provation® Apex

author_avatar
NASDAQ Market News

Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition Study

author_avatar
NASDAQ Market News